Fiscal Year 2023 (FY23) Department of Defense Peer Reviewed Alzheimer's Research Program (PRARP) Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Transforming Diagnosis Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: HT9425-23-PRARP-TDA	Single Principal Investigator (PI) Option: Independent investigators at all career levels (or equivalent). Career Initiation or Transition Partnering PI Option (CITPO): Initiation investigators must have at least 3 years research experience beyond a terminal degree but no more than 7 year within their first independent research position Transition investigators may be at any level, but new to either the Alzheimer's disease/Alzheimer's disease-related dementias (AD/ADRD) and/or traumatic brain injury (TBI) fields	diagnosis and prognosis to better determine the trajectory, long-term outcomes, and impact of AD/ADRD following military service and/or TBI. • Studies are required to prospectively recruit study participants. • Clinical trials are NOT allowed; data and/or human anatomical substances from an existing clinical trial may be used. • Community collaboration is required. • Animal studies are not allowed. • Submission of a Letter of Intent is required prior to full application submission. • Applications must address the FY23 PRARP	 The maximum allowable funding for the entire period of performance is \$2.5 million (M) for total costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 4 years. 	Pre-Application (Letter of Intent): May 31, 2023 5:00 p.m. Eastern time Application: July 25, 2023 11:59 p.m. Eastern time
Transforming Research Award Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: HT9425-23-PRARP-TRA	Single PI Option: Independent investigators at all career levels (or equivalent). CITPO: Initiation investigators must have at least 3 years research experience beyond a terminal degree but no more than 7 years within their first independent research position Transition investigators may be at any level, but new to either the AD/ADRD and/or TBI fields	 Supports transformative research studies that reduce risk of or prevent the development of AD/ADRD with near-term, high-impact outcomes and demonstrate significant positive impact toward improving patient care and/or quality of life. Risk reduction considering TBI is of particular interest. Clinical trials are NOT allowed. Preliminary data are required. Community collaboration is required for projects involving clinical research. Studies with prospective human subjects' enrollment are allowed. Submission of a Letter of Intent is required prior to full application submission. Applications must address the FY23 PRARP Prevention and Risk Reduction Focus Area. CITPO available. 	 The maximum allowable funding for the entire period of performance is \$1.0M for total costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 3 years. 	Pre-Application (Letter of Intent): May 31, 2023 5:00 p.m. Eastern time Application: July 25, 2023 11:59 p.m. Eastern time

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Transforming Care Award Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: HT9425-23-PRARP-TCA	 Single PI Option: Independent investigators at all career levels (or equivalent). CITPO: Initiation investigators must have at least 3 years research experience beyond a terminal degree but no more than 7 years within their first independent research position Transition investigators may be at any level, but new to either the AD/ADRD and/or TBI fields 	 Supports person-centered research that prioritizes the individual with AD/ADRD, their care partner/caregiver, and/or both that clearly demonstrates feasibility and identifies a realistic approach to scaling and implementation. "Care" does not include medical care (such as medical interventions administered by a physician). Clinical trials ARE allowed. Preliminary data are required. Community collaboration is required. Animal studies are <i>not</i> allowed. Submission of a Letter of Intent is <i>required</i> prior to full application submission. CITPO available. Applications must address the FY23 PRARP Individual, Family and Care Partner Focus Area 	 The maximum allowable funding for the entire period of performance is: \$1.0M in total costs for the base option \$1.2M in total costs for the CITPO Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 4 years. 	Pre-Application (Letter of Intent): May 31, 2023 5:00 p.m. Eastern time Application: July 25, 2023 11:59 p.m. Eastern time